Skip to main content
OpenTrials
Completed

NCT Number: NCT02114307

REVITIVE for the Treatment of Patients With Venous Insufficiency

To investigate the efficacy of an electrical stimulation (using the REVITIVE IX device) in treating patients with venous insufficiency.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Academic Department of Vascular Surgery, Charing Cross Hospital

London, W4 8RF, United Kingdom

About this study

This is a pilot randomised control trial to assess the efficacy of a neuromuscular electrical stimulation device to improve venous blood flow and patients' symptoms in patients with chronic venous insufficiency. The Revitive IX device is a neuromuscular electrical stimulation device that gives wide pulse pattern electrical stimulation via foot pads. A cycle of treatment consists of a 30 minute programme of 15 varying waveforms that last a minute each.

Twenty patients with venous insufficiency will be screened according the eligibility criteria. Patients will be randomised to either treatment or control (sham device) group. Patients are advised to use the device 30 minutes a day, everyday, for 6 weeks. Compliance will be monitored with a data logger and diary card.

Primary outcome measure:

a) improvement in venous haemodynamics.

Secondary outcome measures:

  • improvement in lower limb oedema
  • improvement in clinical symptoms
  • reduction in lower limb pain and discomfort
  • improvement in quality of life measures
  • device satisfaction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to understand the study and provide meaningful written informed consent for the study.
  • Willing, able, and committed to participate in the procedures for the full length of the study.
  • All ethnic groups, male or female above the age of 18 years.
  • Diagnosis of chronic venous insufficiency (C2-C5 CEAP classified)
  • Be of non-childbearing potential; or using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the device.
  • Blood pressure currently under moderate control (<160/100mmHg)
  • No current foot ulceration.

Exclusion criteria

  • Has insufficient ability to understand the subject information sheet, consent form and verbal instruction.
  • Has an unstable condition (eg psychiatric disorder, a recent history of substance abuse or otherwise thought to be unreliable or incapable of complying wight he requirements of the clinical investigational plan (CIP).
  • Has any metal implants.
  • Pregnant.
  • Has a cardiac pacemaker, AICD or other implanted electrical device.
  • Has an existing DVT.
  • Has an acute medical condition other than chronic venous insufficiency.
  • Has recent lower limb injury or lower back pain.
  • Has current foot ulceration or other skin ulcers.
  • Has cardiovascular disease.
  • Has foot deformities.
  • Has any disorder that, in the opinion of the investigator, might interfere with the conduct of the study.
  • Has an ABPI < 0.8.

Treatment and study plan

Revitive IX

Device

neuromuscular electrical stimulation device

Primary outcomes

  1. Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV

    Time frame: 0 and 6 weeks

    Femoral vein haemodynamics is measured using ultrasound scan - Time Averaged Mean Velocity

Secondary outcomes

  1. Changes in Limb Swelling, Volume

    Time frame: 0 and 6 weeks

    Lower limb oedema measured before and after using the device at 0 and 6 weeks using a perimeter.

    Limb volume was measured using an optoelectronic limb volumeter. Patients using compression stockings were advised to remove stockings 2 h prior to their appointment. Measurements were taken with the patient seated and the affected leg in a horizontal position. Five readings were taken before and after device usage at Week 0 and Week 6

  2. Clinical Symptoms

    Time frame: 0 and 6 weeks

    Change in clinical symptoms as assessed by the Venous Clinical Severity Score (VCSS) from 0 to 6 weeks, lower score means improvement. Maximum score on VCSS is 30. Minimum score is 0.

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Collaborators

  • Actegy Ltd.

Registry information

Acronym: RVI

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Apr 15, 2014
Registry last updated
Oct 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.